Mark D. Tyson, II, M.D.

Departments

Location

  1. Phoenix, Arizona

Languages

English

Mark D. Tyson II, M.D., is a urologic oncologist, with subspecialty interest in bladder cancer. His clinical focus includes:

  • Treatments for muscle invasive and nonmuscle invasive bladder cancer.
  • Robotic and open cystectomy
  • Ileal conduits and orthotopic neobladders
  • Intravesical therapy for nonmuscle invasive bladder cancer
  • Understanding and improving quality of life for patients with bladder cancer
  • Blue light cystoscopy

In addition to his clinical activities, Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer.

  • SWOG S1602 - A phase III randomized trial to evaluate the influence of BCG strain differences and T-cell priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer.
  • TAR-200-103 - A multicenter study evaluating safety and efficacy of TAR-200 in subjects with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy.
  • SWOG S1605 - A phase II trial evaluating Atezolizumab in treating patients with recurrent BCG-unresponsive non-muscle invasive bladder cancer.
  • UGN-101 - A phase III multicenter trial evaluating the efficacy and safety of MitoGel on ablation of upper urinary tract urothelial carcinoma.
  • UGN-102 - A phase IIb, single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as a chemoablation agent in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence.
  1. Bladder removal
  2. Neobladder reconstruction
  3. Nephrectomy
  4. Partial nephrectomy
  5. Robotic prostatectomy
  6. Urinary conduit surgery
  • Urothelial carcinoma — bladder cancer and upper tract cancer
  • Renal cell carcinoma
  • Prostate cancer
  1. 2015
    ResidentUrology Residency, Urology, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
  2.  
    MPH - Epidemiology and BiostatisticsHarvard T. H. Chan School of Public Health
  3.  
    Fellow - Urologic OncologyDepartment of Urologic Surgery, Vanderbilt University School of Medicine
  4.  
    ResidentUrology Residency, Urology, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
  5.  
    ResidentUrology Residency, Urology, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
  6.  
    ResidentSurgery - Preliminary Residency, Surgery, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
  7.  
    MD - HonorsDartmouth Medical School
  8.  
    BS - Molecular and Cellular Biology, HonorsUniversity of Arizona

Awards and honors

  1. 2018
    Kern Scholar, Science of Health Care Delivery Mayo Clinic
  2. 2018
    Christian Haub Family Career Development Award in Cancer ResearchMayo Clinic
  3. 2017
    Best Paper, Resident CornerEuropean Urology
  4. 2017
    Best ReviewerThe Journal of Urology
  5. 2013
    1st Prize, Health Policy Resident Essay ContestWSAUA
  6. 2012
    2nd Prize, Miley B. Wesson Resident Essay Contest WSAUA
  7. 2012
    100th Percentile - Resident In-Service ExamAmerican College of Physicians
  8. 2009
    Alpha Omega AlphaAlpha Omega Alpha Honor Medical Society
  9. 2006
    Magna Cum LaudeUniversity of Arizona
  10. 2005
    Phi Beta Kappa

Professional memberships

  1. 2018 - present
    MemberMC1633 Intravesical Therapy for Bladder Cancer Publication Working Group, Mayo Clinic Task Forces/Work Groups, Mayo Clinic in Arizona
  2. 2018 - present
    MemberPatient Safety Incident Review Group - AZ, Patient Safety Subcommittee, Continuous Improvement Committee
  3. 2018 - present
    MemberCare Process Model: PSA Screening for Prostrate Cancer, Mayo Clinic Task Forces/Work Groups, Mayo Clinic in Arizona
  4. 2017 - present
    MemberSurgical Quality Subcommittee, Mayo Clinic Hospital
  5. 2017 - present
    MemberBladder Cancer Think Tank, Bladder Cancer Advocacy Network
  6. 2017 - present
    MemberGenitourinary Disease Oriented Group (GU DOG), Department of Urology
  7. 2017 - present
    MemberLower Genitourinary Disease Oriented Group (DOG), Mayo Clinic Task Forces/Work Groups
  8. 2017 - present
    MemberUrology Practice Optimization and Acceleration, Department of Urology
  9. 2015 - present
    MemberSociety of Urologic Oncology
  10. 2015 - present
    MemberVanderbilt Urological Society
  11. 2010 - present
    MemberAmerican Urological Association
  12. 2010 - present
    MemberWestern Section American Urological Association
  13. 2010 - present
    MemberArizona Urological Society
  14. 2010 - present
    MemberPhoenix Urologic Society
see more

Publications